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Abstract
Background: Protease‐activated receptor‐1 (PAR‐1) plays a major role in multiple 
disease processes, including colitis. Understanding the mechanisms coupling PAR‐1 
to disease pathogenesis is complicated by the fact that PAR‐1 is broadly expressed 
across multiple cell types.
Objective: Determine the specific contributions of PAR‐1 expressed by macrophages 
and colonic enterocytes to infectious colitis.
Methods: Mice carrying a conditional PAR‐1 allele were generated and bred to mice 
expressing Cre recombinase in a myeloid‐ (PAR‐1ΔM) or enterocyte‐specific (PAR‐1ΔEPI) 
fashion. Citrobacter rodentium colitis pathogenesis was analyzed in mice with global 
PAR‐1 deletion (PAR‐1−/−) and cell type‐specific deletions.
Results: Constitutive deletion of PAR‐1 had no significant impact on weight loss, crypt 
hypertrophy, crypt abscess formation, or leukocyte infiltration in Citrobacter colitis. 
However, colonic shortening was significantly blunted in infected PAR‐1−/− mice, and 
these animals exhibited decreased local levels of IL‐1β,	IL‐22,	IL‐6,	and	IL‐17A.	In	con‐




Protease‐activated receptor‐1 (PAR‐1) is a G protein‐coupled recep‐
tor activated by cleavage of the N‐terminal extracellular domain, 
revealing an encrypted ligand. PAR‐1 activation has been demon‐
strated to be a significant determinant of disease pathogenesis in 
multiple experimental settings, including inflammatory patholo‐
gies, infection, and cancer.1‐3 However, the precise mechanisms by 
which PAR‐1 mediates disease pathogenesis remain underdefined. 
A significant factor complicating the understanding of the role of 
PAR‐1 in disease is the fact that PAR‐1 is expressed by numerous 
cell types, including multiple subtypes of immune cells, endothelial 
cells, fibroblasts, renal parenchymal cells, neurons, and stressed/
transformed epithelial cells.2,4‐8 Note that PAR‐1 represents the pri‐
mary means of thrombin‐mediated platelet activation in humans but 
is not expressed by murine platelets.9 Given the plethora of PAR‐1 
expressing effector cells, dissecting any cell type‐specific mecha‐
nisms	linking	PAR‐1	to	disease	pathogenesis	is	challenging.	Studies	
in gene‐targeted mice with global PAR‐1 deficiency have been highly 
informative, but any readouts in these animals represent a summa‐
tion of all the cell type‐specific mechanisms coupling this receptor 
to a given disease process. Indeed, we hypothesize that PAR‐1 has a 
complex role in Citrobacter rodentium colitis infection, playing both 
beneficial and detrimental roles in disease pathogenesis that are 
strongly dependent on the cell type expressing PAR‐1.
In order to begin to define the cell type‐specific mechanisms 
linking PAR‐1 to disease pathogenesis we generated mice carrying 
a	 conditional	 “floxed”	 PAR‐1	 allele.	 This	 provided	 a	 means	 to	 de‐
lete PAR‐1 in specific cellular compartments. Our initial studies in 
these animals have focused on a well‐established murine model of 
infectious colitis using Citrobacter rodentium.10,11 C rodentium is a 
naturally occurring gram‐negative enteric pathogen that can infect 
mice but not humans. C rodentium infection in mice causes an inflam‐
matory colitis that shares many important pathogenic mechanisms 
with human enteropathogenic and enterohemorrhagic Escherichia 
coli, making this experimental system highly clinically relevant.10,11 
Moreover, previous studies have established that PAR‐1 is a signifi‐
cant determinant of C rodentium pathogenesis.12	These	studies	sug‐
gested that PAR‐1 drives disease pathologies in C rodentium colitis. 
In	 particular,	 PAR‐1	was	 identified	 as	 a	 key	 driver	 of	 Th17‐related	
immunity in this setting.12 In the studies presented here, C rodentium 
infection was analyzed in mice with global PAR‐1 deletion, as well as 
deletion	limited	to	myeloid	cells	and	intestinal	epithelia.	These	stud‐
ies show that myeloid‐associated PAR‐1 promotes weight loss, crypt 
abscess formation, and local elaboration of IL‐1β. In contrast, intes‐
tinal epithelial‐associated PAR‐1 limits crypt abscess formation and 
weight loss, but does not significantly impact local cytokine elabo‐
ration.	The	apparent	opposing	roles	of	these	two	PAR‐1	expressing	
cellular compartments would not have been evident without the 
ability to dissect the role of PAR‐1 in a cell type‐specific fashion, 
speaking to the experimental utility of these novel mice.
2  | MATERIAL S AND METHODS
2.1 | Mice
All mice used in these studies were backcrossed at least eight gen‐
erations	onto	a	C57BL/6	background.	Mice	with	a	constitutive	de‐
letion of PAR‐1 (PAR‐1−/−) have been previously described.13 Mice 
carrying a conditional “floxed” PAR‐1 allele (PAR‐1fl) were generated 
from	 C57BL/6N	 embryonic	 stem	 cells	 purchased	 from	 EUCOMM	
carrying	LoxP	sites	 flanking	Exon	2	and	FRT	sites	 flanking	a	β‐ga‐
lactosidase reporter and neomycin selection cassette (Figure 1). 
Founder	animals	were	 interbred	with	C57BL/6J‐derived	mice	con‐
stitutively expressing Flp recombinase.14	 Subsequent	 deletion	 of	
the β‐galactosidase reporter and neomycin selection components of 
results in global knockouts, PAR‐1ΔM mice exhibited lower levels of IL‐1β, but not
Th17‐related	cytokines	(ie,	IL‐22,	IL‐6,	IL‐17A).	Infected	PAR‐1ΔEPI mice exhibited in‐
creased crypt hypertrophy and crypt abscess formation, but local cytokine elabora‐
tion was similar to controls.
Conclusions: These	studies	reveal	complex,	cell	type‐specific	roles	for	PAR‐1	in	mod‐
ulating the immune response to Citrobacter colitis that are not readily apparent in 
analyses limited to mice with global PAR‐1 deficiency.
K E Y W O R D S
Citrobacter rodentium, colitis, enterocytes, myeloid cells, PAR‐1
Essentials
• Generation of novel mice carrying a conditional protease‐
activated receptor‐1 (PAR‐1) allele.
• PAR‐1 promotes distinct aspects of the response to C ro-
dentium colitis in an effector cell type‐specific fashion.
• Myeloid PAR‐1 drives weight loss, epithelial damage, and
IL‐1β secretion in infectious colitis.
• Intestinal epithelial cell‐associated PAR‐1 limits epithelial
damage.
the targeted allele were confirmed in the offspring by polymerase 
chain	 reaction	 (PCR).	The	Flp	 recombinase	was	subsequently	bred	
out. Mice carrying the targeted PAR‐1 allele with LoxP sites flanking 
Exon	2	were	interbred	with	established	C57BL/6J‐derived	mice	ex‐
pressing Cre recombinase under the control of the LysM promoter to 
generate mice homozygous for the “floxed” allele and carrying LysM 
F I G U R E  1  Characterization	of	mice	carrying	a	conditional	PAR‐1	allele.	A,	Schematic	of	the	WT,	targeted,	and	Cre	recombined	PAR‐1	
alleles. Note that Cre recombination of the LoxP sites results in deletion of all of exon 2, which represents 93% of the coding region. P1, P2, 
and	P3	represent	the	primers	used	to	genotype	these	animals.	See	the	Appendix	S1	for	details.	B,	PAR‐1	mRNA	expression	(kidney	tissue)	is	
indistinguishable	between	WT	(n	=	4)	and	homozygous	PAR‐1fl/fl	mice	(n	=	5),	but	significantly	greater	than	that	in	established	PAR‐1−/− mice 
(n	=	3)	(*P < .05). C, PCR analyses of peripheral blood DNA from homozygous PAR‐1fl/fl mice and PAR‐1fl/fl mice expressing Cre recombinase 
under the control of the LysM promoter (PAR‐1ΔM). Consistent with the presence of myeloid and non‐myeloid cells in peripheral blood, 
both the non‐recombined and recombined allele are seen in the PAR‐1ΔM cohort. D, PCR analyses of bone marrow‐derived macrophages 
generated from PAR‐1fl/fl and PAR‐1ΔM mice demonstrating near complete recombination in monocytes from the PAR‐1ΔM animals. E, PCR 
analyses of DNA from colonic tissue harvested from PAR‐1fl/fl mice and PAR‐1fl/fl mice expressing Cre recombinase under the control of 
the Villin promoter (PAR‐1ΔEPI). Consistent with the presence of both epithelial and non‐epithelial cells, both the non‐recombined and 




















































































Cre recombinase (PAR‐1ΔM) driving Cre expression in myeloid cells.15 
PAR‐1fl	mice	were	separately	interbred	with	established	C57BL/6J‐
derived mice expressing Cre recombinase under the control of a 
Villin promoter driving Cre expression in intestinal epithelia16 to 
generate mice homozygous for the “floxed” allele and carrying the 
Villin Cre recombinase transgene (PAR‐1ΔEPI). Age‐ and sex‐matched 
cohorts of 8‐ to 12‐week‐old mice were used in all experiments. All 
mice used in these experiments were co‐housed from birth. Refer 
to the supporting information for details regarding the genotyping 
strategy. All experiments were approved by the Institutional Animal 
Care and Use Committee at Cincinnati Children's Hospital Medical 
Center and animal care was per the institutional guidelines.
2.2 | Generation of bone marrow‐derived 
macrophages
Bone marrow‐derived macrophages were generated as previously 
described.17 Briefly, bone marrow was flushed from femurs and 
tibias of mice and resuspended in DMEM (10‐013‐CV, Corning) 
containing	 10%	 fetal	 bovine	 serum	 (SH30071.03,	 Hyclone),	 1%	
penicillin/streptomycin (15140‐122, Gibco), and 40 ng/mL human 
M‐CSF	(gift	from	P.	Murray,	St.	Jude	Children's	Research	Hospital,	
Memphis,	TN).	Bone	marrow	was	plated	on	tissue	culture	plastic	for	
5 to 7 days. Macrophages were collected by scraping, resuspended 
to 1 × 106 cells/mL, and plated on 12‐well tissue culture plates at 
1 × 106	cells/well.	The	following	morning,	media	was	aspirated	and	
fresh DMEM containing 10% bovine calf serum and 1% penicillin/
streptomycin prior to use.
2.3 | Citrobacter rodentium murine colitis
C rodentium colitis was induced in mice essentially as previously 
described.11,18 Briefly, approximately 1 × 109 colony‐forming units 
(CFU) of C rodentium suspended in 100 μL	PBS	was	administered	via	
gavage. Note that cohorts of control and experimental mice within 
a given experiment were always infected in parallel using the same 
suspension. Infection was confirmed by analyses of stool C rodentium 
colony‐forming units (CFUs) grown in MacConkey agar 3 days after 
infection. C rodentium intestinal burden was monitored throughout 
the experiment by measurement of CFUs in stool samples as previ‐
ously	described	(see	Appendix	S1	in	supporting	information	for	de‐
tails).11,18 Any mice without evidence of infection were eliminated 
from	 further	 analyses.	 The	 mice	 were	 monitored	 throughout	 the	
study period and harvested 14 days after infection.
2.4 | Histology, immunohistochemistry, and 
cytokine measurements
Formalin fixed, paraffin‐embedded histological tissue sections were 
stained with hematoxylin and eosin (H&E)19 or immunohistochemi‐
cally	 stained	 for	 macrophages	 (anti‐Iba1;	 Fujifilm	Wako	 catalog	 #	
013‐27691),20	CD3+	T	cells	(anti‐CD3,	Roche,	catalog#	790‐4341),21 
and	 CD4+	 T	 cells	 (anti‐CD4,	 Abcam	 ab183685),22 as previously 
described.	 Sections	 were	 also	 stained	 for	 CD8	 (Cell	 Signaling	
Technology,	#98941	clone	D4W2Z,	Danvers,	MA)	at	1:300	dilutions,	
using	 the	 UltraVision	 LP	 detection	 system	HRP‐DAB	 kit	 (Thermo	
Scientific,	 TL‐015‐HD).	 Cytokines	 in	 colonic	 tissue	 homogenates	
were	measured	using	Luminex	Bead	Technology	 (R&D	Systems)	as	
previously described.23	Note	that	all	quantitive	histological	analyses	
were done by a reviewer blinded to animal genotype.
2.5 | Statistical analyses
Statistical	analyses	were	generated	using	GraphPad	Prism	software,	
version	 4.0	 (GraphPad	 Software).	 The	 specific	 analyses	 used	 are	
noted in the figure legends.
3  | RESULTS
3.1 | Generation of mice carrying a conditional 
PAR‐1 allele
Mice carrying a conditional “floxed” PAR‐1 allele (PAR‐1fl) were 
generated	 from	C57BL/6	embryonic	 stem	cells	 (EUCOMM)	as	de‐
scribed in the Methods section (Figure 1A). Comparisons of PAR‐1 
expression	 by	 qRT‐PCR	 between	WT,	 homozygous	 PAR‐1fl/fl, and 
PAR‐1−/− mice demonstrated that the imposition of the LoxP sites 
had no impact on PAR‐1 expression (Figure 1B). In order to begin 
to dissect the cell type‐specific mechanisms coupling PAR‐1 to in‐
fectious colitis pathogenesis, we interbred PAR‐1fl/fl mice with es‐
tablished mice expressing Cre recombinase under the control of the 
LysM promoter,15 generating mice with a myeloid cell‐specific PAR‐1 
deletion. As expected, analyses of DNA from peripheral blood of 
mice homozygous for the floxed allele and carrying the LysM Cre 
transgene (PAR‐1ΔM) revealed partial recombination of the allele, 
consistent with the presence of myeloid and non‐myeloid cells in 
peripheral blood (Figure 1C). Analyses in bone marrow‐derived mac‐
rophages revealed that recombination was very efficient (Figure 1D). 
We	also	 interbred	PAR‐1fl/fl mice with established mice expressing 
Cre recombinase under the control of the Villin promoter,16 gen‐
erating mice with an intestinal epithelia‐specific PAR‐1 deletion 
(PAR‐1ΔEPI). As expected, PCR analyses of DNA extracted from colonic 
tissue revealed the presence of both the recombined and non‐recom‐
bined alleles, consistent with the presence of epithelial and non‐epi‐
thelial cells in the samples (Figure 1E). Both male and female PAR‐1ΔM 
and PAR‐1ΔEPI mice were generated in expected Mendelian ratios, 
 appeared healthy, were able to breed, and exhibited normal life spans.
3.2 | Myeloid‐ and epithelial‐associated PAR‐1 
play opposing roles in mediating epithelial damage 
associated with C rodentium colitis
As a prelude to studies in mice with cell type‐specific deletions in 
PAR‐1, we first challenged established mice with a constitutive de‐
letion in PAR‐1 (PAR‐1−/−)	 and	 wild‐type	 (WT)	 controls	 in	 parallel	
with ~109 CFU of C rodentium via oral gavage. Paralleling previous 
reports,12 PAR‐1−/− and control mice tolerated the infection and ex‐
perienced similar changes in body weight over the first 10 days of 
the	 challenge.	 There	was	 a	 trend	 toward	 increased	weight	 loss	 in	
the PAR‐1−/− cohort by day 14 postinfection, but this did not reach 
statistical significance (Figure 2A). C rodentium CFUs in stool were 
measured	at	days	3,	7,	and	14	postinfection.	There	was	a	trend	to‐
ward increased CFUs in stool samples from PAR‐1−/− mice relative to 
control animals 3 days postinfection, but this did not reach statisti‐
cal	significance	(Figure	2B).	The	relative	CFUs	in	stool	samples	from	
days 7 and 14 postinfection were similar between genotypes across 
each time point, suggesting that there was no major difference in 
bacterial clearance or overall infection burden between PAR‐1 gen‐
otypes (Figure 2B). Colons harvested from both genotypes were 
significantly shorter than colons harvested from uninfected mice, 
F I G U R E  2   PAR‐1 is a significant determinant of C rodentium colitis. PAR‐1−/−	(n	=	11)	and	WT	(n	=	7)	mice	were	infected	in	parallel	with	
~109 C rodentium	CFUs	by	oral	gavage	and	monitored	over	a	14‐day	time	frame.	A,	Weight	loss	was	similar	in	PAR‐1−/− mice relative to 
controls over the 14 day experiment. (P	=	n.s.,	mixed	effects	two‐way	ANOVA).	B,	Infectious	load	as	measured	by	C rodentium CFUs in 
stool	was	not	statistically	different	between	genotypes	at	any	of	the	time	points	evaluated	(Mann‐Whitney	U test). C, As expected, colons 
harvested from infected mice were significantly shorter than those harvested from uninfected mice. Global deletion of PAR‐1 significantly 
blunted the shortening of the colon, suggesting that PAR‐1 drives some aspects of the inflammatory response in this setting (P values 
generated	using	a	two‐way	ANOVA).	D,	Typical	examples	of	hypertrophic	crypts	in	colonic	tissue	harvested	from	infected	WT	and	PAR‐1−/− 
relative	to	normal	crypts	in	uninfected	mice.	The	black	line	represents	a	typical	crypt	measurement.	E,	The	degree	of	crypt	hypertrophy	
tended to be more significant in colons harvested from PAR‐1−/− mice relative to controls, but this did not reach statistical significance (two‐
way	ANOVA).	F,	Examples	of	crypt	abscesses	(arrowheads)	in	colons	harvested	from	infected	WT	and	PAR‐1−/− mice, as well as uninfected 
colonic tissue cut in the same plane. G, No genotype‐dependent differences were noted in the number of crypt abscesses per colon (Mann‐



























































































































consistent with the fact that colon length is known to inversely cor‐
relate with the severity of inflammation (Figure 2C). More impor‐
tantly, PAR‐1−/− mice challenged with C rodentium had significantly 
longer colons compared to control animals infected in parallel, sug‐
gesting that PAR‐1 is driving inflammation and colon damage in this 
context.
C rodentium colitis results in a hyperproliferative response in 
the epithelia, resulting in a significant lengthening of the colonic 
crypts and thus providing another marker of disease severity.11 
Colonic	crypt	hypertrophy	was	quantitated	by	measuring	the	length	
of ~30‐40 crypts throughout the entire distal colon in each animal. 
As expected, C rodentium infection resulted in a significant increase 
in	 crypt	 length	 relative	 to	 unchallenged	mice	 (Figure	 2D).	 This	 in‐
crease tended to be more pronounced in PAR‐1−/− mice, but this did 
not reach statistical significance (Figure 2E). C rodentium colitis also 
results in damage to the colonic epithelia, leading to loss of crypts 
and the development of crypt abscesses,11 which are characterized 
by intense inflammation, loss of goblet cells, and a neutrophilic ex‐
udate in the glandular lumen. Crypt abscesses and crypt loss were 
also enumerated throughout the entire distal colon and were similar 
between genotypes (Figure 2F,G).
PAR‐1 is expressed by multiple cell types in the colon that could 
contribute to C rodentium colitis pathogenesis. In order to better 
characterize the impact of PAR‐1 on the inflammatory response in‐
fectious colitis, we challenged PAR‐1ΔM mice and PAR‐1fl/fl control 
animals in parallel with ~109 CFUs of C rodentium and analyzed 
them over the same 14‐day time course as was done with infected 
PAR‐1−/− mice. In contrast to mice with complete PAR‐1 deletion, 
PAR‐1ΔM mice lost significantly less body weight relative to control 
animals (Figure 3A). However, myeloid‐specific PAR‐1 deletion had 
no significant impact on C rodentium intestinal load based on mea‐
surement of stool CFUs (Figure 3B), suggesting that the genotype‐
dependent differences in body weight are not related to differences 
in bacterial clearance or overall infectious burden. Paralleling ob‐
servations in mice with global PAR‐1 deficiency, colons harvested 
from Citrobacter‐challenged PAR‐1ΔM mice were significantly 
longer than those harvested from controls challenged in parallel 
(Figure 3C). Histological analyses of crypt length demonstrated that 
the degree of crypt hypertrophy in PAR‐1ΔM mice was comparable 
to that in controls (Figure 3D). Also contrasting with observations 
in PAR‐1−/− mice, deletion of PAR‐1 limited to myeloid cells resulted 
in	significantly	fewer	crypt	abscesses	(Figure	3E,F).	Together,	these	
data suggest that myeloid cell‐associated PAR‐1 is modulating key 
aspects	of	the	host	 immune	response	 in	this	setting.	These	exper‐
iments	were	 repeated	 twice	with	 similar	 results	 (Figure	S1	 in	 sup‐
porting information).
PAR‐1 is also expressed by intestinal epithelia, particularly in the 
context of inflammatory challenges.24	To	define	the	role	of	colonic	
epithelial‐associated PAR‐1 in C rodentium colitis, we challenged 
mice with an intestinal epithelial specific PAR‐1 deletion (PAR‐1ΔEPI) 
F I G U R E  3   Myeloid‐associated PAR‐1 promotes epithelial damage in C rodentium colitis. A, Control (PAR‐1fl/fl,	n	=	8)	and	mice	with	a	
myeloid cell‐specific deletion in PAR‐1 (PAR‐1ΔM,	n	=	6)	were	infected	with	~109 C rodentium CFUs by oral gavage and monitored over 
14 days. PAR‐1ΔM lost significantly less body weight than PAR‐1fl/fl mice (P < .01., mixed effects two‐way ANOVA model). B, C rodentium 
CFUs in the stool were similar between genotypes at each time point evaluated. C, Paralleling observations in PAR‐1−/− mice, myeloid‐
specific deletion of PAR‐1 significantly blunted the shortening of the colon associated with Citrobacter colitis (P values generated using a 
two‐way ANOVA). D, Deletion of PAR‐1 in myeloid cells had no significant impact on the degree of crypt hyperplasia (P values generated 
using a two‐way ANOVA). E and F, Crypt abscesses (arrowhead) were more abundant in colons harvested from Citrobacter‐infected control 
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and control mice with C rodentium in parallel. Paralleling results in 
global PAR‐1 knockouts and PAR‐1ΔM mutants, bacterial load in the 
stool was similar between genotypes over the 14‐day experiment 
(data not shown). In contrast to PAR‐1ΔM mice, PAR‐1ΔEPI tended 
to lose more weight during the infection than control animals, but 
this did not reach statistical significance (Figure 4A). PAR‐1ΔEPI mice 
exhibited no difference in gross shortening of the colon relative to 
controls (Figure 4B). Histological analyses of intestinal tissue 14 days 
after infection demonstrated a significantly greater degree of crypt 
hypertrophy in PAR‐1ΔEPI mice relative to controls (Figure 4C,D), indi‐
cating that epithelial‐associated PAR‐1 contributes to the hypertro‐
phic response in this setting. Contrasting observations in PAR‐1ΔM 
mice, PAR‐1ΔEPI animals demonstrated an increased number of crypt 
abscesses relative to controls 14 days after infection (Figure 4E,F). 
Together,	 these	 data	 suggest	 that	 intestinal	 epithelial‐associated	
PAR‐1 limits intestinal damage in infectious colitis.
3.3 | PAR‐1 is not critically required for clearance of 
C rodentium from the gut
Given that PAR‐1 expressed by myeloid cells promoted epithelial 
damage and weight loss in Citrobacter colitis, we next investigated 
the possibility that myeloid‐associated PAR‐1 may be critical for 
clearing the bacteria. Clearance of C rodentium colitis typically oc‐
curs by day 21 after infection with ~109 CFUs.11 In order to more 
definitively	determine	 if	myeloid‐associated	PAR‐1	 is	 required	to	
clear the bacteria, we infected cohorts of PAR‐1ΔM and PAR‐1fl/
fl mice with ~ 109 C rodentium CFUs and followed the animals for 
F I G U R E  4   Intestinal epithelial‐associated PAR‐1 limits mucosal damage in C rodentium	colitis.	A,	Weight	loss	following	Citrobacter 
infection was not significantly different in mice with intestinal epithelial deletion of PAR‐1 (PAR‐1ΔEPI,	n	=	10)	relative	to	control	animals	
(n	=	7)	infected	in	parallel	(P	=	n.s.,	mixed	effects	two‐way	ANOVA	model).	B,	Deletion	of	intestinal	epithelia‐associated	PAR‐1	had	no	
significant impact on the degree of colonic shortening following Citrobacter infection (P values generated using a two‐way ANOVA). In 
contrast to observations in PAR‐1ΔM, deletion of PAR‐1 in intestinal epithelia resulted in a greater degree of crypt hypertrophy (C and D) 































































































































21 days. Paralleling previous results, PAR‐1ΔM mice lost signifi‐
cantly less weight than control animals over the first 14 days of 
the experiment. PAR‐1ΔM mice also recovered body weight faster 
than control mice over the last 7 days of the experiment (Figure 
S2	 in	supporting	 information).	Neither	PAR‐1ΔM mice nor control 
animals had detectable Citrobacter CFUs in the stool 21 days after 
infection.	 Similarly,	 PAR‐1−/−	 mice	 and	 WT	 controls	 completely	
cleared Citrobacter by 21 days postinfection (data not shown), in‐
dicating that PAR‐1 plays an important role in regulating the host 
response	to	this	pathogen,	but	is	not	critically	required	for	bacte‐
rial clearance.
3.4 | Role of PAR‐1 in macrophage and T cell 
recruitment to infected colons
In order to better define the roles of PAR‐1 expressed by myeloid 
and colonic epithelial cells on the immune response to Citrobacter, 
we immunostained distal colonic tissue harvested from mutant 
mice and control animals 14 days after Citrobacter infection for 
markers	of	activated	macrophages	(Iba1)	and	CD3+	T‐cells	(CD3).	
Iba1‐staining macrophages were sparsely present in uninfected 
colons, and generally located at the base of the crypts, with oc‐
casional Iba1‐stained cells present higher up in the crypts of un‐
infected colons (Figure 5). As expected, abundant Iba1‐stained 
macrophages were present in the colonic tissue harvested from 
Citrobacter‐infected mice (Figure 5). Macrophages were particu‐
larly abundant in the base of the crypts and in the inflammatory 
edema that formed in between the epithelial and muscularis lay‐
ers. Additionally, significant numbers of macrophages could be 
found	throughout	the	crypts	 in	some	areas	 (Figure	5).	We	quan‐
tified the relative infiltration of macrophages into the colonic 
tissue using ImageJ software following a previously established 
protocol.25 Global deletion of PAR‐1 had no impact on the relative 
degree of Iba1‐stained macrophages present in infected colonic 
tissues (Figure 5). Paralleling these results, neither myeloid spe‐
cific deletion of PAR‐1 (PAR‐1ΔM) nor intestinal epithelial deletion 
(PAR‐1ΔEPI) had any significant impact on the relative degree of 
macrophage infiltration into infected colonic tissues (Figure 5).
We	 also	 compared	 CD3+	 T‐cell	 infiltration	 into	 infected	 co‐
lonic tissue by immunostaining for CD3. Only occasional scattered 




the base of the crypts and extending higher up into the crypts in 
infected	mice	 (Figure	 6).	 T	 cells	were	 enumerated	 throughout	 the	
distal colon of infected mice and expressed as a function of the sur‐
face	area	of	the	tissue	analyzed.	Enumeration	of	CD3+	T	cells	in	the	
F I G U R E  5   PAR‐1 is not a significant determinant of macrophage accumulation in Citrobacter‐infected	colonic	tissue.	Shown	are	examples	
of colonic tissue sections stained for macrophages (Iba1) from uninfected colons, and Citrobacter‐infected colons harvested from three 
separate experiments (14 days after infection) comparing PAR‐1−/−	mice	and	WT	mice,	PAR‐1fl/fl and PAR‐1ΔM mice, and PAR‐1fl/fl and 
PAR‐1ΔEPI Citrobacter infection resulted in a significant increase in macrophage infiltration relative to that observed in uninfected colons. 
Quantitation of the relative degree of Iba1 staining using ImageJ software revealed no significant PAR‐1 genotype dependent differences. 
Note that the data presented represent three distinct experiments comparing results in PAR‐1−/−	versus	WT	mice,	PAR‐1ΔM versus PAR‐1fl/fl 












































































crypts showed that global PAR‐1 deletion had no significant impact 
on	 this	 parameter	 (Figure	 S3	 in	 supporting	 information).	 Similarly,	
deletion of PAR‐1 specifically in colonic epithelial cells had no sig‐
nificant	effect	on	CD3+	T‐cell	infiltration	relative	to	control	animals	
(Figure	S3).	However,	myeloid‐specific	deletion	of	PAR‐1	resulted	in	
a modest (~30%) but statistically significant diminution in the num‐
ber	 of	 CD3+	 T	 cells	 infiltrating	 infected	 colonic	 tissue	 relative	 to	
control	animals	 (Figure	6).	 In	order	to	better	delineate	this	relative	
genotype‐dependent	difference	 in	T‐cell	 infiltration,	colonic	 tissue	
from infected PAR‐1ΔM mice and controls was immunostained for 
CD4. Consistent with the fact that CD4 effector cells play a major 
role in clearance of Citrobacter, abundant CD4+ cells were present in 
the colons of infected mice and were comparable in number to CD3+ 
T	cells.	No	PAR‐1	genotype‐dependent	differences	in	the	number	of	
CD4+ cells infiltrating infected colonic tissue were observed, indi‐
cating	that	the	modest	genotype‐dependent	differences	in	CD3+	T‐
cell	infiltration	was	driven	by	non‐CD4	expressing	T	cells.	Consistent	
with the previous findings showing that CD8+ cells are dispensable 
for the immune response to C rodentium,26 immunostaining for CD8 
revealed only occasional CD8+ cells scattered throughout infected 
colonic tissues from both PAR‐1fl/fl and PAR‐1ΔM mice that were not 
different	between	genotypes	(Figure	S4	in	supporting	information).
3.5 | PAR‐1 is a key regulator of cytokine 
elaboration in C rodentium colitis
In order to better define the role of PAR‐1 in leukocyte functions 
in the context of C rodentium colitis we measured the levels of mul‐
tiple cytokines in colonic homogenates that are known to contrib‐
ute toward the pathogenesis of this colitis model.10‐12 As expected, 
the local amounts of each of the cytokines measured (ie, IL‐1β,	IL‐6,	
IL‐17A, IL‐22, IFNγ, Mip‐1α, IL‐18) were significantly higher in colonic 
tissue from infected mice versus uninfected mice. Consistent with 
previous reports,12 global deletion of PAR‐1 resulted in a significant 
diminution in the levels of IL‐1β,	 IL‐6,	 IL‐17A,	 and	 IL‐22	 (Figure	7).	
These	results	suggest	that	PAR‐1	is	an	important	modulator	of	 im‐
mune functions in Citrobacter colitis, including functions important 
for	 the	 development	 of	 Th17‐related	 immunity.	 No	 genotype‐de‐
pendent differences were noted in the levels IFNγ, Mip‐1α, or IL‐18 
in comparisons of colonic tissue from infected PAR‐1−/− and con‐
trol	mice	 (Figure	 S5	 in	 supporting	 information).	However,	 it	 is	 no‐
table that there were was a trend toward higher levels of IL‐18 in 
uninfected PAR‐1−/−	colonic	tissue	relative	to	uninfected	WT	tissue	
(Figure	 S5),	 suggesting	 that	 PAR‐1	may	be	 a	 negative	 regulator	 of	
IL‐18 secretion under homeostatic conditions, but this did not reach 
statistical significance.
In contrast to global PAR‐1 deletion, myeloid‐specific deletion of 
PAR‐1 resulted in a significant diminution in colonic IL‐1β levels in 
Citrobacter‐infected	animals,	but	had	no	significant	 impact	on	 IL‐6,	
IL‐17A, or IL‐22. Myeloid PAR‐1 deletion also had no significant im‐
pact on the levels of IFNγ, Mip‐1α, or IL‐18 in infected animals, which 
was similar to observations in PAR‐1−/−	and	WT	animals	infected	sep‐
arately. Also paralleling results in PAR‐1−/− mice, colons from unin‐
fected PAR‐1ΔM demonstrated a trend toward higher levels of IL‐18 
relative	to	colons	from	uninfected	control	animals	(Figure	S5).	There	
were no statistically significant differences in any of the cytokines 
measured in colonic tissue from infected PAR‐1ΔEPI mice and con‐
trols	(Figure	7	and	Figure	S5).
To	 better	 define	 the	 mechanism	 underlying	 the	 genotype‐de‐
pendent differences in IL‐1β secretion, we challenged thioglycolate‐
induced peritoneal macrophages harvested from PAR‐1−/−, PAR‐1ΔM, 
and appropriate control mice with thrombin, C rodentium lysate, or 
both. As expected, the C rodentium lysate robustly induced IL‐1β 
secretion by macrophages of each genotype. However, thrombin 
F I G U R E  6  Deletion	of	myeloid‐associated	PAR‐1	limits	CD3+	T‐cell	accumulation	into	Citrobacter‐infected	colons.	Shown	are	typical	
examples of colonic tissue sections from uninfected and Citrobacter‐infected PAR‐1fl/fl and PAR‐1ΔM mice stained for CD3 (top panel) or 
CD4	(bottom	panel).	Also	shown	are	the	number	of	CD3+	and	CD4+	T	cells	in	each	colon	as	a	function	of	the	surface	area	of	colonic	tissue	
analyzed. As expected, Citrobacter	infection	resulted	in	a	significant	increase	in	CD3+	and	CD4+	T	cell	infiltration	into	the	colon	compared	




























































stimulation had no effect on IL‐1β secretion regardless of the pres‐
ence	or	absence	of	PAR‐1	(Figure	S6	in	supporting	information).
4  | DISCUSSION
A major obstacle to understanding the precise mechanisms coupling 
PAR‐1 to any disease process has been the fact that this receptor is 
expressed by multiple cell types, making PAR‐1 capable of influenc‐
ing host response through distinct cell type‐specific mechanisms.4,5 
A prime example of this concept is previous studies illustrating that 
PAR‐1, in general, plays a significant role in regulating the response 
to multiple inflammatory challenges, including C rodentium coli‐
tis.5,12,27‐30	The	studies	presented	here	serve	to	bridge	a	key	knowl‐
edge gap by demonstrating that PAR‐1 has very different downstream 
effects depending on the cell type expressing the receptor. In the 
context of C rodentium colitis, activation of PAR‐1 expressed by my‐
eloid cells drives weight loss, epithelial damage, and local IL‐1β secre‐
tion. Despite the fact that myeloid‐associated PAR‐1 drives multiple 
inflammatory processes apparently detrimental to the host in this 
F I G U R E  7   PAR‐1 regulates the expression of multiple cytokines in C rodentium colitis in a cell type‐specific fashion. Levels of multiple 
cytokines known to play a role in C rodentium colitis were measured in colonic homogenates from three different experiments: global PAR‐1 
deletion (top row), myeloid PAR‐1 deletion (middle row), enterocyte PAR‐1 deletion (bottom row). As expected, Citrobacter infection (black 
line) resulted in a significant increase in all of the cytokines measured relative to levels in uninfected mice (green line). Global PAR‐1 deletion 
resulted in a significant decrease in the local expression of IL‐1β,	IL‐6,	IL‐17A,	and	IL‐22.	In	contrast,	myeloid	deletion	of	PAR‐1	resulted	in	a	
significant decrease in IL‐1β, but not the other cytokines measured. Deletion of PAR‐1 in intestinal epithelia (PAR‐1ΔEPI) did not significantly
impact	local	levels	of	any	of	the	cytokines	evaluated.	(The	data	shown	represent	the	mean	±	SEM	with	overlaid	scatter	plots,	*P < .05, 
























































































































































































































































































































































































































































context,	 it	 is	 not	 required	 for	 effective	 clearance	 of	 the	 bacteria.	
Conversely, colonic epithelial‐associated PAR‐1 limits weight loss and 
epithelial damage, but does not appear to directly impact macrophage 
or	T‐cell	functions.	These	studies	highlight	the	critical	importance	of	
dissecting individual cell type‐specific mechanisms coupling PAR‐1 to 
a disease process in vivo. Although studies in global PAR‐1 deficient 
mice are highly informative, analyses of PAR‐1−/− mice alone failed 
to reveal the opposing effects of myeloid‐ and epithelial‐associated 
PAR‐1 on key aspects of infectious colitis demonstrated here. In addi‐
tion to delineating important cell type‐specific mechanisms coupling 
PAR‐1 to infectious colitis, these studies provide a proof of concept of 
the power of these conditional PAR‐1 mutants to enhance knowledge 
of the role of PAR‐1 in the pathogenesis of other diseases.
Multiple previous studies have shown that PAR‐1 plays a signif‐
icant	role	in	colitis	pathogenesis.	This	is	true	in	models	of	infectious	
colitis, as well as models relying on toxins/chemicals that promote 
colitis.12,31,32 However, previous studies did not directly explore the 
role of specific PAR‐1 expressing effector cells in vivo. For exam‐
ple, macrophage‐associated PAR‐1 activation was suggested to play 
a role in the generation of a pro‐inflammatory milieu in colitis that 
drives epithelial damage.12 However, these previous studies relied 
on in vitro analyses of isolated cells to draw conclusions about spe‐
cific PAR‐1 effector cells.12	 The	 studies	 presented	 here	 represent	
the first direct analyses of specific PAR‐1 effector cell populations 
in vivo and reveal that myeloid‐associated PAR‐1 is a crucial modu‐
lator of the host response in infectious colitis. Following Citrobacter 
infection, myeloid‐associated PAR‐1 promoted epithelial damage, as 
evidenced by the significant mitigation of weight loss, colonic short‐
ening, and crypt abscess formation and was a major determinant of 
local IL‐1β secretion in colitis. Notably, previous studies have shown 
that IL‐1β promotes epithelial barrier disruption and weight loss in 
Citrobacter colitis,33 suggesting that the relative decrease in IL‐1β se‐
cretion observed in PAR‐1ΔM may, at least in part, explain the differ‐
ences in the clinical phenotype. It is unclear which myeloid cells are 
responsible for the genotype‐dependent differences in colonic IL‐1β 
levels observed here. In vitro analyses of macrophages derived from 
PAR‐1 mutants and controls exposed to thrombin and/or Citrobacter 
lysate demonstrated no thrombin/PAR‐1 dependent differences in 
IL‐1β	secretion.	This	may	be	because	myeloid	cells	other	than	mac‐
rophages are driving the observed PAR‐1 dependent differences in 
IL‐1β secretion in vivo, but the in vitro data must be interpreted with 
caution.	The	cues	that	lead	to	IL‐1β secretion in vivo in response to 
Citrobacter are likely far more complex than what can be produced 
in an in vitro experimental approach. Indeed, even the activator of 
PAR‐1	in	this	context	cannot	be	definitively	determined.	Therefore,	
additional analyses beyond the scope of the current study will be 
needed	to	definitively	answer	this	question.
Interestingly, neither deletion of myeloid‐ or intestinal epithelial‐
associated PAR‐1 recapitulated the significantly lower levels of cyto‐
kines	that	are	part	of	a	Th17	helper	T‐cell	response	(ie,	IL‐6,	IL‐22,	and	
IL‐17A) observed in mice with global PAR‐1 deletion. Macrophages 
can	be	an	important	source	of	IL‐6,34,35 but the data presented here 
suggest that PAR‐1 mediated macrophage functions are not the sole 
source	of	IL‐6	in	Citrobacter colitis. It is possible that incomplete dele‐
tion of macrophage‐associated PAR‐1 in PAR‐1ΔM mice could, in part, 
explain	the	lack	of	a	significant	decrease	in	IL‐6	observed	in	these	an‐
imals. However, our data indicate that the recombination efficiency 
in	macrophages	was	 quite	 high.	Moreover,	 deletion	of	myeloid‐as‐
sociated PAR‐1 resulted in a phenocopy of other key observations 
in PAR‐1‐/‐ mice, including the significant decrease in colonic IL‐1β in
infected mice, and the trend toward an increase in local levels of IL‐18 
observed in uninfected mice. It would seem more likely that there 
are	additional	non‐myeloid	cellular	compartments	that	generate	IL‐6	
in	a	PAR‐1	dependent	manner	in	this	context.	For	example,	IL‐6	can	
be expressed by fibroblasts and endothelial cells,36‐39 both of which 
have been implicated in PAR‐1 dependent inflammatory processes in 
other contexts.40,41	IL‐22	is	produced	by	multiple	T‐cell	and	NK‐cell	
subsets,42	whereas	IL‐17A	is	secreted	by	CD4+	TH17	cells.43	Whether	
the observed differences in IL‐17A secretion are driven by resident 
CD4+	TH17	cells	or	cells	secondarily	recruited	also	remains	to	be	de‐
fined. It is also conceivable that PAR‐1 signaling could directly influ‐
ence	T‐cell	functions.	There	are	significant	data	from	in	vitro	studies	
showing	that	human	T	cells	express	PAR‐1,	and	that	PAR‐1	activation	
promotes	 T‐cell	 inflammatory	 functions,	 including	 cytokine	 secre‐
tion.6,44‐46	To	our	knowledge,	the	potential	of	PAR‐1,	or	even	PARs	in	
general,	to	influence	murine	T‐cell	functions	has	not	been	rigorously	
explored. Fortunately, the plethora of established Cre recombinase 
expressing cell lines available would provide the opportunity to ex‐
plore the cell type‐specific mechanisms coupling PAR‐1 to colitis and 
other	disease	processes	 in	multiple	cell	 types,	 including	T‐cell	sub‐
sets, dendritic cells, endothelial cells, and fibroblasts.
It is notable that deletion of myeloid PAR‐1 resulted in a modest 
but	 statistically	 significant	decrease	 in	CD3+	T‐cell	 infiltration	 into	
infected	colonic	tissues.	While	these	findings	could	suggest	that	my‐
eloid‐associated	PAR‐1	promotes	T‐cell	recruitment	 in	this	context,	
other explanations seem more likely. Global elimination of PAR‐1 
(PAR‐1−/−)	had	no	significant	 impact	on	CD3+	T‐cell	 infiltration	 into	
infected colons. Moreover, colonic infiltration of CD4+ cells, the pri‐
mary	effector	T‐cells	in	Citrobacter colitis, was similar in PAR‐1ΔM mice 
and controls. Consistent with the recognized importance of the CD4 
response in Citrobacter colitis,11 CD4+ cells represented the majority 
of	the	CD3+	cells	observed.	Therefore,	it	seems	more	likely	that	the	
genotype‐dependent	differences	in	CD3+	T‐cell	infiltration	observed	
in PAR‐1ΔM mice are a secondary phenomenon, and reflect relative 
differences	in	non‐CD4+	T‐cells	responding	to	areas	of	tissue	dam‐
age/inflammation. CD8+ cells were sparse in infected colonic tissues 
and did not appear to be PAR‐1 genotype dependent, suggesting that 
the modest difference in CD3+ cells observed in PAR‐1ΔM mice and 
controls	 is	due	 to	differences	 in	double	negative	T‐cell	 infiltration.	
Further studies will be needed to better define the direct and indi‐
rect	roles	of	PAR‐1	in	regulating	T‐cell	functions	in	this	context.
We	also	interrogated	the	role	of	PAR‐1	expressed	by	colonic	ep‐
ithelia in C rodentium colitis. In contrast to myeloid cell‐associated 
PAR‐1, PAR‐1 expressed by intestinal epithelia limits pathological 
changes in the context of Citrobacter colitis. PAR‐1ΔEPI mice exhib‐
ited more significant weight loss than control animals, had increased 
numbers of crypt abscesses, and more pronounced crypt hypertro‐
phy. PAR‐1 expressed by this cellular compartment did not appear to 
play a major role in regulating leukocyte functions, as there were not 
significant differences seen in leukocyte infiltration or the levels of 
local cytokines. Although the precise mechanisms remain to be de‐
termined, it is notable that previous studies have shown that PAR‐1 
activation can promote epithelial cell survival and proliferation, cell 
death, or loss of barrier functions, depending on the context.7,47,48 
More specifically, previous studies suggested that thrombin‐me‐
diated PAR‐1 activation induces intestinal epithelial apoptosis and 
increases intestinal permeability.48 In contrast, activated protein C 
(APC) has been implicated in maintaining epithelial tight junctions, 
thus promoting epithelial barrier integrity.49 It is tempting to spec‐
ulate that loss of APC‐mediated PAR‐1 activation is responsible for 
the phenotype observed here in PAR‐1ΔEPI mice.
The	focus	of	this	study	was	to	shed	light	on	the	cell	type‐specific	
roles of PAR‐1 in C rodentium	colitis.	The	activating	protease(s)	re‐
sponsible	for	these	effects	remain	to	be	determined.	The	relatively	
recent generation of gene‐targeted mice carrying specific mutations 
in the N‐terminal region of PAR‐1 biasing the receptor toward throm‐
bin‐ or APC‐mediated activation will be invaluable tools in defining 
the role of these specific PAR‐1 activators in colitis and other disease 
processes.50 Of course, multiple other proteases in addition to APC 
and thrombin are capable of activating PAR‐1, including bacterial 
derived proteases.8,51,52 Indeed, distinct proteases may be primarily 
responsible for activating different PAR‐1 effector cell subsets, de‐
pending on the context.
In summary, these studies demonstrate that PAR‐1 expressed 
by different tissue compartments can play distinct, and even appar‐
ently opposing roles in disease pathogenesis. Analyses in mice with 
constitutive PAR‐1 deficiency, while highly informative, cannot de‐
lineate these distinct cell type‐specific mechanisms. Given the fact 
that PAR‐1 is expressed by a plethora of cell types and that PAR‐1 
has been shown to play a major role in multiple disease settings, 
future studies are likely to reveal additional important roles for cell 
type‐specific	PAR‐1	across	many	disease	spectra.	The	novel	animals	
presented here are likely to be important tools in the study of PAR‐1 
signaling in other inflammatory pathologies, models of infection, and 
cancer pathogenesis. Given that a PAR‐1 antagonist is now approved 
by	United	States	Food	and	Drug	Administration	for	clinical	use	in	hu‐
mans,53 understanding the role of this receptor in disease pathogene‐
sis in cell type‐specific mechanistic detail is of significant importance.
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